文献速递血管炎

ANCA相关血管炎患者中质子泵抑制剂与组胺2受体拮抗剂的骨折风险比较:巢式病例对照研究

Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested case-control study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究基于日本全国住院数据库,纳入2010年7月至2018年3月新诊断ANCA相关血管炎并接受糖皮质激素诱导治疗的患者,比较质子泵抑制剂(PPI)与组胺2受体拮抗剂(H2RA)与骨折风险的关联。多因素分析显示,与H2RA相比,PPI使用与骨折风险显著相关(调整OR 3.76,95%CI 1.37-10.3)。

要点

  • 在AAV住院诱导治疗患者中,PPI使用与骨折风险显著高于H2RA使用相关。
  • 骨折患者中PPI使用比例为91.3%,对照组为80.2%。
  • 从AAV治疗至骨折的中位时间为52天。

核心结论

  • 在主要為高龄的AAV接受缓解诱导治疗患者中,PPI使用者骨折风险高于H2RA使用者。

研究设计与样本

  • 巢式病例对照研究,利用2010年7月至2018年3月日本全国住院数据库,从22 821例新诊断AAV患者中识别149例骨折患者,按1:4匹配对照,匹配年龄、性别、AAV治疗时长和财年。

主要发现

  • 骨折患者中位年龄77岁,99例(66%)为女性,从AAV治疗至骨折的中位时间为52天。
  • 病例组PPI使用比例为91.3%(136/149),对照组为80.2%(478/596)。
  • 多因素分析调整年龄、性别、BMI、吸烟习惯、Charlson合并症指数、肾衰竭、双膦酸盐及同一财年后,PPI使用与骨折显著相关(调整OR 3.76;95%CI 1.37,10.3)。

临床怎么用

  • 对AAV接受糖皮质激素诱导治疗的患者,处方抑酸药时可考虑H2RA替代PPI以降低骨折风险,尤其高龄患者。

局限性

  • 回顾性数据库研究,可能存在未测量混杂因素;仅纳入住院患者,骨折事件可能低估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Whether acid suppressants [proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs)] are associated with bone fractures in patients with ANCA-associated vasculitis (AAV) treated with glucocorticoids remains unclear. This study compared PPIs with H2RAs in terms of the risk of bone fractures in patients with AAV who received in-hospital induction therapy with glucocorticoids. METHODS: We retrospectively identified 149 patients with fractures among 22 821 patients newly diagnosed with AAV in 1730 hospitals using a nationwide inpatient database from July 2010 to March 2018. We conducted 1:4 case-control matching. Age, sex, duration of AAV treatment and fiscal year were matched between the cases and controls. A conditional logistic regression analysis was conducted to assess the association between acid suppressants and fractures. RESULTS: Of all enrolled patients with fractures, the median age was 77 years, and 99 (66%) were female. The median duration from AAV treatment to fracture was 52 days. The proportion of patients using PPIs was 91.3% (136 of 149) and 80.2% (478 of 596) in the case and control groups, respectively. Compared with H2RA use, PPI use was significantly associated with fractures after adjustment for age, sex, BMI, smoking habit, Charlson comorbidity index, renal failure, bisphosphonate and same fiscal year according to a multivariate analysis (adjusted odds ratio, 3.76; 95% CI: 1.37, 10.3). CONCLUSION: PPI users had a higher risk of fractures than H2RA users among mostly advanced-age patients with AAV with remission induction therapy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Miyano S, Michihata N, Sada KE, et al. Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested case-control study. Rheumatology (Oxford). 2021. PMID: 33067623. doi:10.1093/rheumatology/keaa594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。